Here’s what could change next.
President Donald Trump is reportedly preparing to roll out a new Medicare pilot program that could allow certain seniors to receive reimbursement for CBD-based treatments, according to a Thursday report from The Washington Post.
If implemented, the proposal would mark a significant shift in federal health policy—particularly for older Americans coping with chronic pain, cancer-related symptoms, and rising prescription drug costs.
The report comes as Trump is also weighing broader reforms to federal policy. One option under discussion involves reclassifying certain substances under federal law, a move that could have wide-ranging effects on medical research, business regulations, taxes, and Medicare coverage.
Why CBD Is at the Center of the Discussion
CBD is commonly used by Americans seeking relief from pain, sleep issues, and anxiety. Surveys cited by Forbes suggest that a majority of adults have tried CBD at some point, though most seniors currently pay for it out of pocket.
Despite its popularity, the substance has largely remained outside the traditional medical system. That could change if the Centers for Medicare & Medicaid Services (CMS) moves forward with a limited reimbursement trial.
According to The Washington Post, CMS could launch the pilot program as early as next year.
A Limited Pilot, Not a Blanket Benefit
Financial analyst Michael Ryan, founder of MichaelRyanMoney.com, cautioned that the proposal would be narrow in scope.
“This is a controlled test, not a sweeping expansion,” Ryan told Newsweek. “The goal is to see whether this substance can transition from over-the-counter supplements into regulated medical coverage. Most seniors shouldn’t expect immediate access.”
Reports this week also indicate Trump may sign an executive order aimed at expanding medical cannabis access—while keeping the focus squarely on symptom management, not recreational use.
Potential Cost Savings for Medicare
Supporters argue the real motivation behind the pilot may be financial.
Medicare currently spends billions each year treating chronic pain and chemotherapy side effects, often relying on costly opioid medications.
“The bigger issue is cost control,” Ryan explained. “This substance may serve as a lower-cost, non-addictive option for pain management. If the data supports it, this could become one of the most meaningful benefit experiments for fixed-income seniors in years.”
Ryan emphasized that any pilot would likely be restricted to areas such as oncology, palliative care, or chronic pain treatment, using pharmaceutical-grade products under strict medical oversight.
“This isn’t free for everyone,” he said. “Eligibility would be limited, dosing would be controlled, and products would be tightly regulated.”
What Seniors Should Expect Next
Kevin Thompson, CEO of 9i Capital Group, echoed that assessment, urging patience.
“For now, seniors should expect more discussion than immediate change,” Thompson told Newsweek. “Any policy shift would begin as a pilot program with clear guardrails around prescribing, approval, and reimbursement.”
Alex Beene, a financial literacy instructor at the University of Tennessee at Martin, said even a pilot would represent a major policy shift.
“Medicare has historically been cautious about covering alternative therapies,” Beene noted. “This would signal a meaningful change in how the federal government views this and its potential role in senior care.”
A Broader Shift Could Follow
Analysts say that if Medicare eventually begins reimbursing treatments, the industry itself would change.
“Once Medicare gets involved, this stops being a loosely regulated supplement market,” Ryan said. “Safety standards rise, but cheaper unregulated products disappear. Long-term, if outcomes are positive, this could become permanent—and force the medical community to take cannabinoid-based treatments more seriously.”
For now, Trump’s reported plan remains in the exploratory phase. But for millions of seniors watching health care costs climb, the proposal signals that Medicare reform—and cost containment—may be back at the center of the national conversation.